Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 2
2006 2
2007 3
2009 2
2011 4
2012 6
2013 8
2014 6
2015 9
2016 4
2017 1
2018 4
2019 6
2020 5
2021 11
2022 8
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC.
Yildirim ME, Karadurmuş N, Ökten İN, Türk HM, Urakçı Z, Arslan Ç, Çelik S, Dane F, Şendur MAN, Bilir C, Karabulut B, Cicin İ, Çubukçu E, Karaca M, Ozcelik M, Artaç M, Tanrikulu E, Alacacioglu A, Açıkgöz Ö, Öven B, Geredeli Ç, Çil T, Harputluoğlu H, Kefeli U, Bozkurt O, Tural D, Sakin A, Yalçın Ş, Gumus M. Yildirim ME, et al. Among authors: cubukcu e. J Oncol Pharm Pract. 2024 Apr 13:10781552241241004. doi: 10.1177/10781552241241004. Online ahead of print. J Oncol Pharm Pract. 2024. PMID: 38613329
Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data.
Sütcüoğlu O, Doğan A, Yilmaz F, Şahin AB, Şahin TK, Esen SA, Erol C, Üner A, Özet A, Turan N, Eraslan E, Deligönül A, Odabaş H, Günel N, Uçar G, Dede DŞ, Dizdar Ö, Çubukçu E, Öksüzoğlu ÖB, Emre Yildirim M, Yazici O, Özdemir N. Sütcüoğlu O, et al. Among authors: cubukcu e. Pancreas. 2023 Apr 1;52(4):e235-e240. doi: 10.1097/MPA.0000000000002238. Epub 2023 Oct 25. Pancreas. 2023. PMID: 37816170
Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?
Güner G, Aktaş BY, Başal FB, Demirkazık A, Gürsoy P, Demirci U, Erman M, Yumuk PF, Şenler FÇ, Çakar B, Çiçin İ, Öztürk A, Coşkun HŞ, Çubukçu E, Işıkdoğan A, Ölmez ÖF, Tatlı AM, Karaağaç M, Şakalar T, Eralp Y, Korkmaz T, Kılıçkap S. Güner G, et al. Among authors: cubukcu e. J Cancer Res Clin Oncol. 2023 Nov;149(14):13271-13277. doi: 10.1007/s00432-023-05190-3. Epub 2023 Jul 22. J Cancer Res Clin Oncol. 2023. PMID: 37480524
A Multicenter Study of Genotype Variation/Demographic Patterns in 2475 Individuals Including 1444 Cases With Breast Cancer in Turkey.
Boga I, Ozemri Sag S, Duman N, Ozdemir SY, Ergoren MC, Dalci K, Mujde C, Parsak CK, Rencuzogullari C, Sonmezler O, Yalav O, Alemdar A, Aliyeva L, Bozkurt O, Cetintas S, Cubukcu E, Deligonul A, Dogan B, Ornek Erguzeloglu C, Evrensel T, Gokgoz S, Senol K, Tolunay S, Akyurek E, Basgoz N, Gökçe N, Dundar B, Ozturk F, Taskin D, Demirtas M, Cag M, Diker O, Olgun P, Tug Bozdogan S, Dundar M, Bisgin A, Temel SG. Boga I, et al. Among authors: cubukcu e. Eur J Breast Health. 2023 Jul 3;19(3):235-252. doi: 10.4274/ejbh.galenos.2023.2023-2-5. eCollection 2023 Jul. Eur J Breast Health. 2023. PMID: 37415649 Free PMC article.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel BC, Acar O, Aksoy S, Baytemur NK, Sahin E, Cabuk D, Basaran G, Paydas S, Yaren A, Guven DC, Erdogan AP, Demirci U, Yasar A, Bayoglu İV, Hizal M, Gulbagci B, Paksoy N, Davarci SE, Yilmaz F, Dogan O, Orhan SO, Kayikcioglu E, Aytac A, Keskinkilic M, Mocan EE, Unal OU, Aydin E, Yucel H, Isik D, Eren O, Uluc BO, Ozcelik M, Hacibekiroglu I, Aydiner A, Demir H, Oksuzoglu B, Cilbir E, Cubukcu E, Cetin B, Oktay E, Erol C, Okutur SK, Yildirim N, Alkan A, Selcukbiricik F, Aksoy A, Karakas Y, Ozkanli G, Duman BB, Aydin D, Dulgar O, Er MM, Teker F, Yavuzsen T, Aykan MB, Inal A, Iriagac Y, Kalkan NO, Keser M, Sakalar T, Menekse S, Kut E, Bilgin B, Karaoglanoglu M, Sunar V, Ozdemir O, Turhal NS, Karadurmus N, Yalcin B, Nahit Sendur MA. Kahraman S, et al. Among authors: cubukcu e. Future Oncol. 2023 Mar;19(10):727-736. doi: 10.2217/fon-2022-1287. Epub 2023 May 3. Future Oncol. 2023. PMID: 37133230
85 results